Doctors test 'Smart Bomb' radiation for aggressive prostate cancer

NCT ID NCT06379217

Summary

This early-stage study is testing a personalized radiation treatment for men with metastatic neuroendocrine prostate cancer, an aggressive form of the disease. Doctors first scan each patient's tumors to see which of three specific targets is most present, then deliver a matching radioactive drug designed to attack those targets. The main goals are to check if this approach is safe and to see early signs of whether it can help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NEUROENDOCRINE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York, 10017, United States

  • Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    München, 80377, Germany

  • Novartis Investigative Site

    Rostock, 18057, Germany

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • Novartis Investigative Site

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Novartis Investigative Site

    London, NW3 2QG, United Kingdom

  • Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

  • Stanford University

    Palo Alto, California, 94304, United States

Conditions

Explore the condition pages connected to this study.